mRNA Platform Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Usability, By mRNA Type, By End User, By Region & Competition, 2020-2030F

Description

The Global mRNA Platform Market was valued at USD 7.30 billion in 2024 and is projected to grow at a CAGR of 3.56% through 2030. The mRNA (messenger RNA) platform is an advanced biotechnological innovation that enables synthetic RNA molecules to deliver genetic instructions to cells, prompting the production of specific proteins. This approach has demonstrated significant success in vaccine development and is expanding into treatments for a range of diseases. Notably, in September 2023, BioNTech SE partnered with CEPI to accelerate the development of an mRNA-based Mpox vaccine, underscoring the platform's importance in preparing for emerging infectious threats. By mimicking the natural role of RNA in the body, synthetic mRNA sequences are engineered to prompt immune responses or support therapeutic protein production. These technologies are increasingly adopted due to their adaptability, speed of development, and effectiveness, particularly in public health emergencies and personalized medicine applications.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 7.30 Billion
Market Size 2030	USD 8.93 Billion
CAGR 2025-2030	3.56%
Fastest Growing Segment	Self-Amplifying mRNA
Largest Market	North America

Key Market Drivers

Technological Advancements

Advances in lipid nanoparticle (LNP) delivery systems have enhanced the stability and cellular uptake of mRNA molecules, improving their efficacy. These innovations were instrumental in the success of COVID-19 mRNA vaccines. Modified mRNA sequences are now more stable and less immunogenic, extending vaccine shelf life and easing distribution. For example, Sanofi launched a new mRNA research facility at Griffith University in November 2023 to accelerate drug development. Techniques like codon optimization are being refined to maximize protein expression, while synthetic biology tools such as CRISPR-Cas9 allow precise mRNA sequence design for targeted therapies. The development of cost-efficient and scalable manufacturing has also improved the availability of mRNA products during global health crises. Furthermore, enhancements in cold chain logistics and stability at varied temperature ranges reduce dependency on ultra-cold storage. The integration of next-generation sequencing supports precise and rapid design of mRNA-based treatments, enabling therapeutic applications across a broad range of indications.

Key Market Challenges

Vaccine Hesitancy and Misinformation

A critical challenge facing the Global mRNA Platform Market is vaccine hesitancy, fueled by misinformation. Despite scientific validation, concerns around safety, efficacy, and long-term impacts have hindered vaccine uptake. Social media platforms are often sources of misinformation, influencing public perception and eroding confidence in mRNA-based vaccines. This hesitancy can reduce immunization rates, hampering efforts to achieve herd immunity and prolonging outbreaks of preventable diseases. Public mistrust also complicates health campaigns during emergencies, such as pandemics, and may extend skepticism to other public health measures. Low vaccine coverage due to hesitancy not only affects individual health outcomes but also increases pressure on healthcare systems and obstructs disease control efforts at a population level.

Key Market Trends

Increase in the Number of Virtual Trials

The rise of virtual trials is reshaping drug development strategies, including those related to mRNA therapies. Virtual trials use digital platforms for remote data collection, reducing dependence on physical sites and expanding access to more diverse participant populations. CROs and pharmaceutical companies are increasingly adopting technologies such as telemedicine, wearable sensors, and mobile health apps to monitor patient outcomes in real-time. This approach enhances patient engagement, accelerates trial timelines, and reduces operational costs. The decentralized model is proving particularly effective for vaccines and therapies that require global outreach, supporting rapid data acquisition and streamlined regulatory submissions.

Key Market Players

AstraZeneca PLC
Asuragen, Inc.
Catalent Pharma Solutions
Arcturus Therapeutics, Inc.
BioNTech AG
CRISPR Therapeutics Inc.
AKESOgen, Inc.
baseclick GmbH
Accent Therapeutics Inc.
Accanis Biotech F&E GmbH & Co KG

Report Scope:

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Platform Market, By Indication:

Autoimmune Diseases
Cancer
- Personalized Treatment
- Single Cancer Focused
Infectious Diseases
Rare Diseases
Respiratory Diseases

mRNA Platform Market, By Usability:

Prophylactic Vaccines
Therapeutic Drugs
Therapeutic Vaccines

mRNA Platform Market, By mRNA Type:

Nucleoside-Modified mRNA
Self-Amplifying mRNA
Unmodified mRNA

mRNA Platform Market, By End-User:

Hospitals & Clinics
Pharmaceutical Companies
Research Organization

mRNA Platform Market, By Region:

North America
- United States
- Canada
- Mexico
Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

Global mRNA Platform Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mRNA Platform Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
- 5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
- 5.2.3. By mRNA Type (Nucleoside-Modified mRNA , Self-Amplifying mRNA , Unmodified mRNA )
- 5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
5.3. Market Map

6. Asia Pacific mRNA Platform Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Indication
- 6.2.2. By Usability
- 6.2.3. By mRNA Type
- 6.2.4. By End User
- 6.2.5. By Country
6.3. Asia Pacific: Country Analysis
- 6.3.1. China mRNA Platform Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Indication
    - 6.3.1.2.2. By Usability
    - 6.3.1.2.3. By mRNA Type
    - 6.3.1.2.4. By End User
- 6.3.2. India mRNA Platform Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Indication
    - 6.3.2.2.2. By Usability
    - 6.3.2.2.3. By mRNA Type
    - 6.3.2.2.4. By End User
- 6.3.3. Australia mRNA Platform Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Indication
    - 6.3.3.2.2. By Usability
    - 6.3.3.2.3. By mRNA Type
    - 6.3.3.2.4. By End User
- 6.3.4. Japan mRNA Platform Market Outlook
  - 6.3.4.1. Market Size & Forecast
    - 6.3.4.1.1. By Value
  - 6.3.4.2. Market Share & Forecast
    - 6.3.4.2.1. By Indication
    - 6.3.4.2.2. By Usability
    - 6.3.4.2.3. By mRNA Type
    - 6.3.4.2.4. By End User
- 6.3.5. South Korea mRNA Platform Market Outlook
  - 6.3.5.1. Market Size & Forecast
    - 6.3.5.1.1. By Value
  - 6.3.5.2. Market Share & Forecast
    - 6.3.5.2.1. By Indication
    - 6.3.5.2.2. By Usability
    - 6.3.5.2.3. By mRNA Type
    - 6.3.5.2.4. By End User

7. Europe mRNA Platform Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Indication
- 7.2.2. By Usability
- 7.2.3. By mRNA Type
- 7.2.4. By End User
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. France mRNA Platform Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Indication
    - 7.3.1.2.2. By Usability
    - 7.3.1.2.3. By mRNA Type
    - 7.3.1.2.4. By End User
- 7.3.2. Germany mRNA Platform Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Indication
    - 7.3.2.2.2. By Usability
    - 7.3.2.2.3. By mRNA Type
    - 7.3.2.2.4. By End User
- 7.3.3. Spain mRNA Platform Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Indication
    - 7.3.3.2.2. By Usability
    - 7.3.3.2.3. By mRNA Type
    - 7.3.3.2.4. By End User
- 7.3.4. Italy mRNA Platform Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Indication
    - 7.3.4.2.2. By Usability
    - 7.3.4.2.3. By mRNA Type
    - 7.3.4.2.4. By End User
- 7.3.5. United Kingdom mRNA Platform Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Indication
    - 7.3.5.2.2. By Usability
    - 7.3.5.2.3. By mRNA Type
    - 7.3.5.2.4. By End User

8. North America mRNA Platform Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Indication
- 8.2.2. By Usability
- 8.2.3. By mRNA Type
- 8.2.4. By End User
- 8.2.5. By Country
8.3. North America: Country Analysis
- 8.3.1. United States mRNA Platform Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Indication
    - 8.3.1.2.2. By Usability
    - 8.3.1.2.3. By mRNA Type
    - 8.3.1.2.4. By End User
- 8.3.2. Mexico mRNA Platform Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Indication
    - 8.3.2.2.2. By Usability
    - 8.3.2.2.3. By mRNA Type
    - 8.3.2.2.4. By End User
- 8.3.3. Canada mRNA Platform Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Indication
    - 8.3.3.2.2. By Usability
    - 8.3.3.2.3. By mRNA Type
    - 8.3.3.2.4. By End User

9. South America mRNA Platform Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Indication
- 9.2.2. By Usability
- 9.2.3. By mRNA Type
- 9.2.4. By End User
- 9.2.5. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil mRNA Platform Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Indication
    - 9.3.1.2.2. By Usability
    - 9.3.1.2.3. By mRNA Type
    - 9.3.1.2.4. By End User
- 9.3.2. Argentina mRNA Platform Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Indication
    - 9.3.2.2.2. By Usability
    - 9.3.2.2.3. By mRNA Type
    - 9.3.2.2.4. By End User
- 9.3.3. Colombia mRNA Platform Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Indication
    - 9.3.3.2.2. By Usability
    - 9.3.3.2.3. By mRNA Type
    - 9.3.3.2.4. By End User

10. Middle East and Africa mRNA Platform Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Indication
- 10.2.2. By Usability
- 10.2.3. By mRNA Type
- 10.2.4. By End User
- 10.2.5. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa mRNA Platform Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Indication
    - 10.3.1.2.2. By Usability
    - 10.3.1.2.3. By mRNA Type
    - 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia mRNA Platform Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Indication
    - 10.3.2.2.2. By Usability
    - 10.3.2.2.3. By mRNA Type
    - 10.3.2.2.4. By End User
- 10.3.3. UAE mRNA Platform Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Indication
    - 10.3.3.2.2. By Usability
    - 10.3.3.2.3. By mRNA Type
    - 10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global mRNA Platform Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1. Amgen Inc. AstraZeneca PLC
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (In case of listed companies)
- 16.1.5. Recent Developments
- 16.1.6. SWOT Analysis
16.2. Asuragen, Inc.
16.3. Catalent Pharma Solutions
16.4. Arcturus Therapeutics, Inc.
16.5. BioNTech AG
16.6. CRISPR Therapeutics Inc.
16.7. AKESOgen, Inc.
16.8. Baseclick GmbH
16.9. Accent Therapeutics Inc.
16.10.Accanis Biotech F&E GmbH & Co KG